deaths from tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx Approved weight-loss drug contributed to

Future research should prioritize large-scale randomized trials that include diverse patient populations and longer follow-up periods

For individuals at this life stage, a provider may consider a more gradual titration approach based on individual clinical factors

Much like optional cookies, we explore the choices available in B12 supplementation, providing insights into the various options and considerations for a personalized approach to health and wellness

If a dose is missed, standard guidance applies

What to Read Next The 37-year-old PR from Swindon had always kept in shape with the guidance of a personal trainer